

Contents

List of Contributors	xxi
Foreword by Dr. Steven M. Fox	xxiii
Foreword by Laura Eldridge	xxv
Acknowledgments	xxvi
About the Companion Website	xxvii

Part 1 Laying the Groundwork: Principles and Framework for Modern OA Care 1

1	Read with Purpose: How to Approach This Book	3
	<i>Kristin Kirkby Shaw and Hannah Capon</i>	
1.1	Introduction: Why This Book	3
1.2	What to Expect from This Book	3
1.3	Guiding Principles of the OA Blueprint and This Textbook	4
1.4	What Comes Next	5
1.5	Final Thoughts	5
2	The OA Blueprint	6
	<i>Kristin Kirkby Shaw and Hannah Capon</i>	
2.1	The OA Blueprint	6
2.2	Awareness	6
2.3	Screening	7
2.4	Diagnosis	7
2.5	Plan	7
2.6	Recheck	9
2.7	Lifelong Management	9
2.8	Summary	9
3	What We Are Up Against: Understanding OA and Maladaptive Pain	10
	<i>Kristin Kirkby Shaw and Duncan Lascelles</i>	
3.1	The Joint Is an Organ	10
3.2	What Exactly Is Osteoarthritis?	10
3.3	The Disease of OA	11
3.3.1	Molecular Mechanisms of OA	11
	Cartilage Degeneration	12
	The Synovium and Inflammatory Cytokines	12
	Neurogenic Inflammation	13
3.3.2	Macroscopic Changes to the Joint with OA	13
3.3.3	Pathology vs. Radiology	16
3.4	Why Do Dogs Develop OA?	16
3.4.1	Role of Systemic Inflammation	18

3.5	Clinical OA: The Disease of Maladaptive Pain	18
3.5.1	Defining Types of Pain	18
3.5.2	Nociceptive Pain	19
3.5.3	Inflammatory Pain	20
3.5.4	Maladaptive Pain	20
3.5.5	Neuropathic Pain	21
3.5.6	Nociplastic Pain	21
3.6	Generation of Nociceptive Signals in OA	21
3.6.1	The Pain Pathway	21
3.6.2	Joint Innervation	22
3.6.3	Molecular Mediators of OA Pain	23
3.7	Beyond the Biology: The Biopsychosocial Model of Pain	23
3.8	Conclusion	24
	References	24

Part 2 Set the Stage for Success: People, Patients, and Practice Culture 29

4 The Role of Fear and Anxiety in OA Care 31

Margaret Gruen and Michael Khan

4.1	Pain as a Teacher	31
4.1.1	Neurobiology	31
4.2	Behavioral Changes in Dogs as a Result of Chronic OA Pain	31
4.2.1	New and Worsening Fears	32
4.2.2	Aggression	33
4.2.3	Changes to Routine	34
4.3	Behavioral Considerations with Veterinary Care	34
	References	35

5 “But My Dog Isn’t Crying Out.” How to Talk with Caregivers About OA and Pain 37

Hannah Capon

5.1	Before You Skip This Chapter ...	37
5.1.1	What Are Great Outcomes?	37
5.2	Effective Communication in Veterinary Practice	38
5.2.1	Personalized Communication: A Two-Way Exchange	38
5.2.2	Client-Centered Care: The Foundation of Effective Communication	39
5.2.3	The Role of Empathy in Communication	40
5.3	The Biopsychosocial Approach in Veterinary Care	40
5.4	Setting Yourself Up for Success: Sustaining the Best Version of Yourself	41
5.5	Managing Canine OA Is a Journey of Many Legs	41
5.5.1	Screening and Identification	42
5.5.2	Diagnosis	43
5.5.3	Initial Treatment Plan	44
5.5.4	Revised Treatment Plan	46
5.5.5	End of Life Care	46
5.6	Maintaining Caregiver Engagement	47
	References	48

6	It Takes a Village: A Team-Based Approach to Osteoarthritis Management	49
	<i>Jerrod Johnson</i>	
6.1	Introduction	49
6.2	The Team	50
6.2.1	Client Service Representative/Reception Team/Administration Team	50
6.2.2	Veterinary Technician/Nurse	51
6.2.3	Veterinary Assistant	51
6.2.4	Veterinarian	52
6.2.5	Specialist/Referral Team	52
6.2.6	Allied Canine Professionals	52
6.2.7	Caregiver and Patient	53
6.3	Why a Team Approach Matters	53
	References	54
7	Tech to Tech: How to Be the Best OA Advocate for Your Patients	55
	<i>Stephen Niño Cital</i>	
7.1	Introduction	55
7.2	Veterinary Technician Autonomy	55
7.3	Technicians in the Recognition and Advocacy for Physical and Psychological Pain Management	56
7.4	Preparing for the Visit: A Pre-, During-, and Post-Visit Affair	56
7.4.1	Low Stress: Not Just for Psychological Safety, But Patient Comfort	56
7.4.2	Making the Lobby and Exam Room Pain- and Stress-Free	57
7.4.3	The Pre-Visit	57
7.4.4	Post-Visit	57
7.5	The In-hospital Experience	58
7.5.1	Cage/Kennel Setup for Animals in Pain	58
7.5.2	Preparing Procedure and Surgical Tables for Patients to Reduce Pain	58
7.6	Technician-Led Education and Communication	59
7.6.1	Taking Pain (Acute/Chronic)-Focused Histories	59
7.6.2	Educating Clients on Metrology Tools	59
7.6.3	Education on Nutrition	59
7.6.4	Coaching Clients on Lifestyle Adaptations for Animals with Pain	60
7.7	Team Approach to Diagnosis (Tech Focus)	60
7.7.1	Assisting in a Physical Examination	60
7.8	Veterinary Technician-Led Chronic Treatment Appointments	60
7.8.1	Veterinary Technicians Supporting Long-term Treatment Strategies	60
7.8.2	Assisting or Performing Treatments	61
7.9	Conclusion	61
	Reference	62
8	How to Create an OA-Friendly Clinic and Consult	63
	<i>Tamsin Durston</i>	
8.1	Introduction	63
8.2	What It Means to Be a Dog with OA	63
8.3	What This Means for a Dog with OA Visiting the Veterinary Clinic	64
8.4	Promoting Physical and Psychological Safety Within the Clinic	65
8.5	Client Education	68
	References	70

Part 3 From Suspicion to Confirmation: The Art and Science of Diagnosing OA 73

9 When It's Not So Simple: Differential Diagnoses for OA Lameness and Common Comorbidities That May Impact Your Plan 75

Wanda Gordon-Evans

- 9.1 Introduction 75
- 9.2 Differential Diagnoses for OA 76
 - 9.2.1 Immune-Mediated Polyarthritis 76
 - 9.2.2 Septic Arthritis 78
 - 9.2.3 Soft-Tissue Musculoskeletal Injury 79
 - 9.2.4 Periarticular Neoplasia 79
 - 9.2.5 Conditions Affecting the Paws 80
- 9.3 Comorbidities 80
 - 9.3.1 Obesity 81
 - 9.3.2 Systemic Disease 81
 - 9.3.3 Sarcopenia 82
 - 9.3.4 Neurologic Conditions 82
 - 9.3.5 Geriatric Onset Laryngeal Paralysis and Polyneuropathy (GOLPP) 82
 - 9.3.6 Lumbosacral (LS) Disease 82
- References 83

10 It Starts with an Index of Suspicion: Screening Tools for Identifying OA 85

Kristin Kirkby Shaw

- 10.1 Why Screen for OA 85
- 10.2 Predisposing Factors for OA 85
- 10.3 When Do Dogs Start Developing Evidence of OA? 86
- 10.4 What Are the Earliest Signs of OA Pain? 86
- 10.5 WHEN and WHO to Screen for OA 86
- 10.6 Engage Caregivers to Help Identify Signs of OA 88
- 10.7 The 60-Second OA Screening Exam 89
- References 91

11 The Art of the Musculoskeletal Exam: Using Low-Stress Techniques to Establish a Diagnosis of Joint Disease 93

Kristin Kirkby Shaw and Ross Palmer

- 11.1 Obtaining a Comprehensive MSK History 93
 - 11.1.1 Clues in the History 93
 - 11.1.2 The MSK History Questionnaire 93
- 11.2 Why Perform a Low-Stress Musculoskeletal Exam 97
 - 11.2.1 How to Set up for a Successful MSK Exam Experience 97
- 11.3 How to Perform the Low-Stress MSK Exam 98
 - 11.3.1 Observation 98
 - 11.3.2 Palpation 104
 - That "WAS CREAMPI" 105
 - Standing Exam 106
 - Neurologic Screening Exam 107
- 11.4 Individual Limb Assessment 107
 - 11.4.1 Thoracic Limb 108
 - Shoulder 108
 - Axilla 109
 - Elbow 109
 - Antebrachium 109

	Carpus	110
	Metacarpals and Digits	110
11.4.2	Pelvic Limb	110
	Hip	110
	Stifle	110
	Tarsus	113
	Metatarsals and Digits	113
11.5	Juvenile Dog Hip Exam	113
	References	116
12	Diagnostic Imaging Techniques and Radiographic Features of OA	117
	<i>Matthew D. Winter and Danielle Mauragis</i>	
12.1	Introduction to Diagnostic Imaging	117
12.2	Diagnostic Imaging Modalities: Strengths and Limitations	117
12.2.1	Radiography	117
12.2.2	Ultrasound	118
12.2.3	Computed Tomography (CT)	118
12.2.4	Magnetic Resonance Imaging (MRI)	118
12.3	Principles of Radiographic Interpretation	119
12.3.1	Systematic Approach to Interpretation	119
12.4	Organizing Your Approach	120
12.4.1	Description of Abnormal Findings	121
12.4.2	Synthesis	121
12.4.3	Next Steps	121
12.5	Radiographic Features of Osteoarthritis	121
12.5.1	Synovial Volume and Periarticular Swelling	122
12.5.2	Osteophytes	123
12.5.3	Enthesophytes	123
12.5.4	Joint Space Narrowing	125
12.5.5	Changes in Subchondral Bone Opacity	125
12.5.6	Subluxation	126
12.6	Positioning for Success	127
12.7	Joint-specific Imaging	128
12.7.1	Shoulder	128
	Lateral Projection	129
	Caudal-to-Cranial	129
	Pronated Lateral	130
	Supinated Lateral	130
	Bicipital Groove View (Specialized)	130
12.7.2	Elbow	131
	Lateral Positioning (Neutral)	131
	Flexed Lateral	132
	Cranial-to-Caudal	132
	Cranio-15° Medial Caudolateral Oblique	133
12.7.3	Carpus/Metacarpus	135
12.7.4	Lateral Positioning	135
	General Positioning	135
	Neutral Lateral	135
	Flexed Lateral	135
	Extended Lateral	136
	Dorsopalmar Projection	136
	Pronated Dorsopalmar (35° Inward Toward Midline)	137

	Supinated Dorsopalmar (35° Outward from Midline)	137
12.7.5	Pelvis/Hips	139
	Lateral View	139
	Ventrodorsal View	139
	Frog-Leg View	140
12.7.6	Stifle	142
	Neutral Lateral	142
	Caudal-to-Cranial (Preferred)	142
	Cranial-to-Caudal (Alternative)	143
12.7.7	Tarsus	146
	Lateral Positioning	146
	Neutral Lateral	146
	Flexed Lateral	146
	Extended Lateral	147
	Dorsoplantar Projections	147
	Pronated Dorsoplantar (DLPMO) (35° Inward Toward Midline)	147
	Supinated Dorsoplantar (DMPLO) (35° Outward from Midline)	148
12.7.8	Phalanges	150
	Digit Separation for Mediolateral Views	150
	Dorsoplantar Projection (Pelvic Limb)	150
	Dorsopalmar Projection (Thoracic Limb)	151
12.8	Summary	153
	References	153
13	Put a Number on It: Stages, Grades, and Use of Clinical Metrology Instruments for OA	155
	<i>Mark E. Epstein, Kristin Kirkby Shaw, and Hannah Capon</i>	
13.1	Introduction	155
13.2	CMI for Canine Chronic Pain	156
13.2.1	Canine Brief Pain Inventory (CBPI)	157
13.2.2	Canine Orthopedic Index (COI)	158
13.2.3	Liverpool Osteoarthritis in Dogs (LOAD)	159
13.2.4	Client-Specific Outcome Measures (CSOM)	161
13.3	Incorporating a CMI into General Practice	163
13.4	Canine Osteoarthritis Staging Tool (COAST)	163
13.4.1	Why Use COAST	164
13.5	Incorporating COAST Into General Practice	165
	References	166
14	How to Develop and Modify Your Plan	169
	<i>Hannah Capon</i>	
14.1	Introduction	169
14.2	The Bigger Picture of OA Management	170
14.2.1	Frameworks to Guide Development and Modification of Multimodal Care Plans	170
14.2.2	The Blueprint	171
14.2.3	The Canine Osteoarthritis Staging Tool	172
14.2.4	The OA Disease and Illness Model	172
14.2.5	Return to Function Framework	173
14.3	Considering the Evidence	174
14.4	Carving the Initial Plan	175
14.4.1	Clinical Priorities	177
14.4.2	Communication and Contextualized Care	177
14.4.3	Logistics	178

14.5	OA, Acute-on-Chronic Pain – Identifying and Preparing Clients for Flares	179
14.6	Your Role in the Care Plan	179
14.7	Modifying the Care Plan	179
14.7.1	Comfortable and Well-maintained on the Current Treatment Plan	180
14.7.2	Identification of an Insufficient Plan at a Scheduled Reassessment	180
14.7.3	Unexpected Deterioration	181
	References	182

Part 4 Building Your Plan: The Essentials of OA Management 185

15 Pharmaceutical Options for OA Management 187

Melina Zimmerman and Kristin Kirkby Shaw

15.1	Introduction to Pharmaceutical Management of Canine Osteoarthritis	187
15.1.1	Types of Pain Experienced with OA	187
15.2	Nonsteroidal Anti-inflammatory Medications (NSAIDs)	188
15.2.1	Mechanism of Action	188
15.2.2	PGE ₂ as a Therapeutic Target	189
15.2.3	Evidence for Use for OA/Chronic Pain in Dogs	191
15.2.4	Clinical Indications	191
15.2.5	Dosing Recommendations	191
15.2.6	Contraindications and Precautions	192
15.2.7	Potential Side Effects	192
15.2.8	Other Considerations	193
15.3	Anti-Nerve Growth Factor Monoclonal Antibodies (Anti-NGF mAbs)	193
15.3.1	Mechanism of Action	193
15.3.2	Anti-NGF mAbs	195
15.3.3	Evidence for Use for OA/Chronic Pain in Dogs	195
15.3.4	Clinical Indications	195
15.3.5	Dosing Recommendations for Bedinvetmab	195
15.3.6	Contraindications and Precautions	196
15.3.7	Potential Side Effects Reported for Bedinvetmab	196
15.3.8	Other Considerations	197
15.4	Acetaminophen	198
15.4.1	Mechanism of Action	198
15.4.2	Evidence for Use in OA/Chronic Pain in Dogs	198
15.4.3	Clinical Indications	198
15.4.4	Dosing Recommendations	198
15.4.5	Contraindications and Precautions	198
15.4.6	Potential Side Effects	198
15.4.7	Other Considerations	198
15.5	NMDA Antagonists	199
15.5.1	Mechanism of Action	199
15.5.2	Evidence for Use in OA/Chronic Pain in Dogs	199
15.5.3	Clinical Indications	199
15.5.4	Dosing Recommendations	199
	Ketamine	199
	Amantadine	199
	Memantine	200
15.5.5	Potential Side Effects	200
15.5.6	Other Considerations	200
15.6	Gabapentinoids	200

15.6.1	Mechanism of Action	200
15.6.2	Evidence for use in OA/Chronic Pain in Dogs	200
15.6.3	Clinical Indications	201
15.6.4	Dosing Recommendations	201
15.6.5	Contraindications and Precautions	201
15.6.6	Potential Side Effects	201
15.6.7	Other Considerations	201
15.7	Anxiolytics	202
15.7.1	Tricyclic Antidepressants (TCAs)	202
	Mechanism of Action	202
	Evidence for Use in OA/Chronic Pain in Dogs	202
	Clinical Indications	202
	Dosing Recommendations	202
	Contraindications and Precautions	202
	Potential Side Effects	203
	Other Considerations	203
15.7.2	Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)	203
	Mechanism of Action	203
	Evidence for use in OA/Chronic Pain in Dogs	203
	Clinical Indications	203
	Dosing Recommendations	203
	Contraindications and Precautions	203
	Potential Side Effects	203
	Other Considerations	204
15.7.3	Selective Serotonin Reuptake Inhibitors (SSRIs)	204
	Mechanism of Action	204
	Evidence for use in OA/Chronic Pain in Dogs	204
	Clinical Indications	204
	Dosing Recommendations	204
	Contraindications and Precautions	204
	Potential Side Effects	204
	Other Considerations	205
15.7.4	Alpha-2 Adrenergic Agonists	205
	Mechanism of Action	205
	Evidence for use in OA/Chronic Pain in Dogs	205
	Clinical Indications	205
	Dosing Recommendations	205
	Contraindications and Precautions	205
	Potential Side Effects	205
	Other Considerations	205
15.8	Muscle Relaxants	206
	Mechanism of Action	206
	Evidence for use in OA/Chronic Pain in Dogs	206
	Clinical Indications	206
	Dosing Recommendations	206
	Contraindications and Precautions	206
	Potential Side Effects	207
	Other Considerations	207
15.9	Opioids	207
15.9.1	Injectable Full Mu Opioid Agonists	207
	Mechanism of Action	207
	Evidence for use in OA/Chronic Pain in Dogs	207

	Clinical Indications	207
	Dosing Recommendations	207
	Contraindications and Precautions	207
	Potential Side Effects	207
	Other Considerations	207
15.9.2	Oral Opioids	208
	Mechanism of Action	208
	Evidence for use in OA/Chronic Pain in Dogs	208
	Clinical Indications	208
	Dosing Recommendations	208
	Contraindications and Precautions	208
	Potential Side Effects	208
	Other Considerations	208
15.9.3	Oral Transmucosal Opioids	209
	Mechanism of Action	209
	Evidence for use in OA/Chronic Pain in Dogs	209
	Clinical Indications	209
	Dosing Recommendations	209
	Contraindications and Precautions	209
	Potential Side Effects	209
	Other Considerations	209
	References	213
16	The Biggest Impact: Weight Management and Nutrition for Canine OA	219
	<i>Joe Wakshlag, Ernie Ward, and Kristin Kirkby Shaw</i>	
16.1	Introduction: Why This Chapter Is So Important	219
16.2	Defining Excess Adiposity	220
16.2.1	Overweight vs. Obesity	220
16.2.2	Diagnosing Excess Adiposity	221
16.3	Health Implications of Canine Obesity	221
16.3.1	Prevalence	221
16.3.2	Contributors, Comorbidities, and Consequences	222
16.3.3	Obesity and OA	223
16.3.4	Excess Adiposity and Quality of Life	224
16.4	Discussing Excess Adiposity with Caregivers	224
16.4.1	Tips for Talking to Caregivers About Weight Management	224
16.5	How to Develop a Weight Loss Plan	227
16.6	Nutritional Recommendations for Puppies/Growing Dogs	236
16.6.1	Protein Recommendations for Growing Dogs	237
16.6.2	The Importance of Calcium and Phosphorus Balance	237
16.6.3	Gonadectomy and Obesity (and OA)	237
16.6.4	Best Practices for Feeding Growing Puppies	238
16.7	Feeding Geriatric Dogs with OA for Weight Loss	238
16.7.1	Protein Requirements in Aging Dogs	238
16.8	Omega-3 Fatty Acids and Weight Loss	239
16.8.1	Omega-3 Fatty Acid Supplementation Recommendations	239
16.8.2	Dosing Considerations	239
16.9	Barriers to Weight Loss	240
16.9.1	3 Steps to Achieving Client Compliance for Weight Loss	240
	References	242

17 Use It or Lose It: The Crucial Role of Exercise in OA Management 247*Kara Amstutz*

- 17.1 Introduction 247
- 17.2 The Role of Exercise in the Osteoarthritic Patient 247
 - 17.2.1 Exercise Attenuates Pain 247
 - 17.2.2 Caution! The Wrong Type of Exercise Can Induce Pain 248
 - 17.2.3 Exercise Assists with Weight Loss 249
 - 17.2.4 Exercise Modulates Osteoarthritis Progression 249
 - 17.2.5 Exercise Maintains Muscle Mass 250
 - 17.2.6 Exercise Boosts Mobility 250
 - 17.2.7 Exercise Maintains Proprioception 250
 - 17.2.8 Exercise Slows Cognitive Decline 251
- 17.3 Exercise Prescription for the OA Patient 251
 - 17.3.1 Strength Exercises 252
 - 17.3.2 Proprioception and Balance Exercises 253
 - 17.3.3 Joint Range of Motion and Muscle Flexibility Exercises 253
 - 17.3.4 Endurance Exercises 255
 - 17.3.5 Walking 255
- References 257

18 OA Is a Way of Life: Home and Environmental Modifications 260*Hannah Capon*

- 18.1 Introduction 260
- 18.2 The Consequences of Persistent OA Pain 261
 - 18.2.1 Functional Mobility Is Reduced with OA Pain 261
 - 18.2.2 Psychological Safety Is Threatened by OA Pain 262
 - 18.2.3 Comorbidities and Frailty Impact Mobility and Are Common in Dogs with OA Pain 262
 - 18.2.4 Polypharmacy Is Often Employed in Dogs with OA Pain 263
- 18.3 How the Environment Impacts OA and Pain 263
 - 18.3.1 Dogs Can Slip and Fall Too 263
 - 18.3.2 Changes in the Environment Can Contribute to Acute OA Flares 265
- 18.4 The Environment and Patient Welfare: “Freedom from” Often Forgets “Freedom to” 265
 - 18.4.1 Sleep Needs 266
 - 18.4.2 Mental Engagement Needs 266
- 18.5 Environmental Modifications: The Underappreciated Game Changer 267
- 18.6 Making Recommendations Inspired by “Joint Protection” 268
 - 18.6.1 Veterinary Joint Protection in Action 268
 - 18.6.2 When Do You Introduce Veterinary “Joint Protection”? 269
- 18.7 Engaging Your Team and the Caregiver to Implement Change 270
 - 18.7.1 Persuading the Caregiver 271
 - 18.7.2 Cognitive Biases and Beliefs 271
 - 18.7.3 Lack of Understanding 272
 - 18.7.4 Habits and Routines 272
 - 18.7.5 Emotional Factors 272
- 18.8 What Do Environmental Modifications Look Like? 273
 - 18.8.1 Practical Solutions 273
 - 18.8.2 Environmental Modifications for Dogs with Mobility Issues (E.g. OA) 274
- References 277

Part 5 Beyond the Basics: Adjunctive Therapies and Advanced Interventions 281

- 19 Surgical Management of Joint Diseases and Osteoarthritis 283**
Christina DeArmond, Miranda de la Vega, and Laurent Guiot
- 19.1 Introduction 283
 - 19.2 Thoracic Limb Conditions and Associated Surgical Techniques 283
 - 19.2.1 Shoulder 283
 - Osteochondritis Dissecans (OCD) 284
 - Biceps Tendinopathy 284
 - Supraspinatus Tendinopathy 286
 - Shoulder Instability and Luxation 286
 - End-stage Shoulder Disease 287
 - 19.2.2 Elbow 288
 - Fragmented Medial Coronoid Process (FMCP) 288
 - Ununited Anconeal Process (UAP) 290
 - Osteochondritis Dissecans (OCD) 290
 - Elbow Incongruity 291
 - Elbow Luxation 291
 - End-stage Elbow Arthritis 292
 - 19.2.3 Carpus 293
 - Carpal Fractures 293
 - Carpal Hyperextension 293
 - End-stage Carpal Arthritis 295
 - 19.2.4 Digits 295
 - 19.3 Pelvic Limb Conditions and Associated Surgical Techniques 295
 - 19.3.1 Hip 295
 - Hip Dysplasia 295
 - Legg–Calvé–Perthes Disease 299
 - 19.3.2 Stifle 301
 - Cranial Cruciate Ligament Disease 301
 - Patellar Luxation 304
 - Osteochondritis Dissecans (OCD) 308
 - End-stage Stifle Management 309
 - 19.3.3 Tarsus 311
 - OC/OCD 311
 - End-stage Tarsus 311
 - Total Ankle Replacement 312
 - Pantarsal Arthrodesis 312
 - Partial Tarsal Arthrodesis 312
 - References 314

20.5.1	Thermal Energy	323
	Cryotherapy (Ice)	323
	Thermotherapy (Heat Packs)	324
20.5.2	Electromagnetic Energy	324
	Photobiomodulation (PBM)	324
	Pulsed Electromagnetic Field (PEMF)	326
20.5.3	Acoustic Energy	326
	Therapeutic Ultrasound	327
	Extracorporeal Shock Wave Therapy (ESWT)	327
	Electrical Energy	329
20.6	Integrating Rehabilitation into Practice	329
	References	330
21	Joint Support Supplements: Do They Have a Place in Canine OA Management?	333
	<i>Leilani X. Alvarez</i>	
21.1	Introduction	333
21.2	Pharmaceuticals vs. Nutraceuticals	333
21.3	Safety of Supplements	334
21.4	What to Look for in a Quality Supplement	335
21.5	Current Evidence	335
21.5.1	Glucosamine and Chondroitin	335
21.5.2	Omega-3 Fatty Acids	336
21.5.3	Green-lipped Mussel (<i>Perna canaliculus</i>)	338
21.5.4	Undenatured Type II Collagen (UC-II®)	338
21.5.5	Eggshell Membrane (ESM)	338
21.5.6	Hyaluronic Acid (HA)	338
21.5.7	Herbals	338
	Cannabinoids	338
	Curcumin	339
	<i>Boswellia serrata</i>	339
21.5.8	Antioxidants	339
	Astaxanthin (ASX)	340
21.5.9	Injectable Joint Support Products	340
	Polysulfated Glycosaminoglycan (PSGAG, Adequan®)	340
	Pentosan Polysulfate Sodium (PPS, Cartrophen Vet)	341
21.6	Implementation in a Multimodal OA Plan	341
	References	341
22	Intra-Articular Therapies	345
	<i>Jessica Rychel, Lindsey Fry, and Arielle Pechette Markley</i>	
22.1	Introduction to Intra-Articular Therapies for OA	345
22.2	Considerations for Joint Injections	345
22.3	What to Inject Into the Joint	346
22.3.1	Hyaluronic Acid (HA)	346
22.3.2	Corticosteroids	347
22.3.3	Platelet-Rich Plasma (PRP)	347
22.3.4	Autologous Protein Solution (APS)/Autologous Conditioned Serum (ACS)	348
22.3.5	Autogenous Mesenchymal Stem Cells	349
22.3.6	Polyacrylamide Hydrogel	350
22.3.7	Collagen–Elastin Hydrogel Particles	351
22.3.8	Radiosynoviorthesis with Sn-117m (Synovetin OA™)	352
	References	354

23	Acupuncture for OA Management: Scientific Rationale and Practical Recommendations	359
	<i>Lindsey Fry and Arielle Pechette Markley</i>	
23.1	What Is Acupuncture and How Does It Work?	359
23.2	Acupuncture in OA Management	359
23.2.1	Acupuncture for Local Disease Management – Modification of the Inflammatory Joint	360
23.2.2	Acupuncture for Pain Management in OA	360
23.2.3	Acupuncture for Myofascial Dysfunction	362
23.3	The Acupuncture Visit: Practical Tips	362
	References	365
	Part 6 Graceful Goodbyes: Supporting Dogs and Caregivers Through the Final Stages of OA	369
24	When It's Not Quite Time: Palliative and Hospice Care	371
	<i>Sheilah A. Robertson and Bonnie D. Wright</i>	
24.1	Introduction	371
24.2	Palliative and Hospice Care	372
24.2.1	Integrative Medical Approach	372
24.3	Pharmacologic Interventions	373
24.3.1	N-Methyl-D-Aspartate (NMDA) Receptor Antagonists	373
24.3.2	Acetaminophen (Paracetamol)	373
24.3.3	Anxiolytics	374
24.3.4	Corticosteroids	375
24.4	Non-Pharmacologic Modalities	375
24.4.1	Heat	375
24.4.2	Electromagnetic Fields	376
24.4.3	Light Therapy	376
24.4.4	Therapeutic Diets and Supplements	376
24.4.5	Mobility Assistance Devices and Environmental Modifications	376
24.5	Treatment of Myofascial Pain Syndrome	377
24.6	Euthanasia	377
	References	378
25	When Pain Wins: End-of-Life Decision-Making	381
	<i>Mary Gardner</i>	
25.1	Why This Topic Is Important	381
25.2	The Many Facets of Diminished Mobility	381
25.3	The Quality-of-Life Elements	382
25.3.1	Element 1: The Disease and How It Will Progress	382
25.3.2	Element 2: Assessing the Patient's Personality and Emotional Well-being	382
25.3.3	Element 3: Family Beliefs and Differences	383
25.3.4	Element 4: The Four Critical Budgets of Pet Care	383
25.4	Aligning a Family's Capacity With Their Pet's Disease Progression	384
25.4.1	The Pattern of Waiting Too Long	384
25.4.2	Considering a Natural Death	385
25.4.3	Does Science Provide a Clear Answer of "When Is Time"?	385
25.5	The Role of Quality-of-Life Assessment Tools	385
25.5.1	The Top Five Method	386
25.5.2	The Five Freedoms as a Guide for End-of-Life Care	386

25.5.3	Defining Good Days vs. Bad Days	386
25.5.4	Tracking Good Days and Bad Days	387
25.6	An SOS from Denial Island	387
25.7	No Simple Answer – Only Thoughtful Guidance	388
25.7.1	Supporting Families Through the Final Journey	388
	Reference	389

Index	390
--------------	-----